Head and Neck Cancer and ASCO 2022

Reducing oral mucositis in patients treated with CRT using avasopasem manganese

Head and neck cancer at ASCO 2022

Remaining hurdles in liquid biopsies

E3311: exploring deintensification of adjuvant treatment in patients with intermediate risk HPV+ OPC

De-escalation strategies to optimize oncologic control and minimize toxicity

The rationale behind the E3311 trial exploring de-escalated radiation therapy for HPV+ OPV

LIONESS: a personalized cell-free tumor DNA analysis for patients with HNSCC.

KEYNOTE-012: retrospective analysis exploring potential biomarkers for IO in advanced solid tumors

E3311: outcomes by tobacco history in HPV+ oropharynx cancer

Narrower side margin excision for head and neck BCC in the Japanese population

Future directions for head and neck cancer

​​NRG-HN002: Translational analysis of plasma tumor tissue modified viral HPV DNA and outcomes

​​NRG-HN002: chemoradiotherapy for p16-positive low-risk HPV-associated oropharyngeal carcinoma

Investigating novel treatment modalities for HPV-positive oropharyngeal cancers

Phase II trial of pembrolizumab & cabozantinib in patients with recurrent metastatic HNSCC

CA209-9KY: IMRT + nivolumab for recurrent head and neck squamous cell cancer